CSIMarket
 
Healthcare Sector

Medical Laboratories Industry  




Data by Company within Medical Laboratories Industry


  Marketcap Revenues (TTM) Net Income (TTM) Employees
Company (Millions) (Millions) (Millions) Number
Iqvia Holdings Inc $ 37,948 $ 14,681 $ 1,096 79,000
Ge Healthcare Technologies Inc $ 30,448 - $ 0 -
Icon Plc $ 20,651 $ 7,741 $ 505 15,950
Koninklijke Philips Nv $ 18,094 $ 19,966 $ -1,798 82,000
Hologic Inc $ 17,316 $ 4,038 $ 1,667 6,944
Ppd Inc $ 16,999 - $ 0 -
Quest Diagnostics Inc $ 14,215 $ 9,488 $ 858 49,000
Incyte Corporation $ 13,257 $ 3,513 $ 366 2,094
Exact Sciences Corporation $ 11,883 $ 2,292 $ -432 5,361
Pra Health Sciences Inc $ 10,932 $ 3,333 $ 213 35,000
Charles River Laboratories International inc $ 10,053 $ 4,178 $ 490 20,000
Medpace Holdings Inc $ 7,726 $ 1,673 $ 269 3,900
Natera Inc $ 5,139 $ 931 $ -512 2,800
Syneos Health Inc $ 4,464 $ 5,419 $ 71 25,000
Guardant Health Inc $ 2,841 $ 510 $ -508 1,100
Fortrea Holdings Inc $ 2,526 - $ 0 -
Radnet Inc $ 1,720 $ 1,528 $ 12 8,700
Veracyte Inc $ 1,629 $ 329 $ -29 677
National Research Corporation $ 1,135 $ 148 $ 29 -
Fulgent Genetics Inc $ 824 $ 307 $ -50 284
Viridian Therapeutics Inc $ 668 $ 1 $ -198 -
Lightwave Logic Inc $ 562 - $ -21 10
Omniab Inc $ 495 - $ -37 -
Somalogic Inc $ 437 $ 101 $ -141 -
Castle Biosciences Inc $ 431 $ 110 $ 19 200
Mdxhealth Sa $ 429 $ 37 $ -44 -
Caredx Inc $ 411 $ 309 $ -84 446
Nano x Imaging Ltd $ 330 $ 9 $ -113 -
Nuoncology Labs Inc $ 322 - $ 0 -
Maxcyte inc $ 317 $ 41 $ -33 -
Zymergen Inc. $ 251 $ 15 $ -365 -
Butterfly Network Inc $ 232 $ 69 $ -107 -
Celcuity Inc $ 210 - $ -49 -
Luna Innovations Inc $ 200 $ 109 $ -5 236
Fresh2 Group Ltd $ 167 $ 2 $ -15 -
Bionexus Gene Lab Corp $ 157 $ 10 $ -1 -
Invitae Corporation $ 151 $ 481 $ -451 1,500
Absci Corp $ 124 $ 9 $ -112 -
Biodesix Inc $ 112 $ 42 $ -66 -
Kushco Holdings Inc $ 104 $ 114 $ -25 29
Inotiv Inc $ 82 $ 582 $ -338 -
Enzo Biochem Inc $ 68 $ 71 $ -46 412
Personalis Inc $ 58 $ 67 $ -110 -
Sera Prognostics Inc $ 55 $ 0 $ -42 -
Dermtech Inc $ 52 $ 13 $ -120 -
Science 37 Holdings Inc $ 46 - $ 77 -
Exagen Inc $ 40 $ 53 $ 13 -
Centogene N v $ 28 $ 53 $ -36 500
Check cap Ltd $ 25 - $ 17 -
Medtech Acquisition Corporation $ 24 - $ -1 -
Psychemedics Corp $ 21 $ 23 $ -2 -
American Shared Hospital Services $ 15 $ 20 $ 1 -
Malachite Innovations Inc $ 14 $ 11 $ 0 -
Akumin Inc $ 12 $ 751 $ -154 -
Bioaffinity Technologies Inc $ 8 $ 0 $ -11 -
Ispecimen inc $ 6 $ 10 $ -11 -
Halberd Corporation $ 5 - $ 0 -
Evolutionary Genomics Inc $ 5 $ 0 $ -4 -
Vyant Bio Inc $ 5 $ 1 $ -23 -
Biocept Inc $ 2 - $ -39 135
Grapefruit Usa Inc $ 1 $ 0 $ -4 -
Opgen inc $ 1 $ 3 $ -36 -
Advanced Container Technologies Inc $ 1 $ 5 $ -1 22
U s Stem Cell Inc $ 0 $ 0 $ -3 -
Hh and l Acquisition Co - - $ 9 -
Burning Rock Biotech Limited - $ 82 $ -141 -
Genetron Holdings Ltd - $ 94 $ -118 862
Laboratory Corporation Of America Holdings - $ 14,877 $ 1,281 75,500
Delwinds Insurance Acquisition Corp - - $ 0 -
Renalytix Plc - $ 1 $ -34 -
Aclarion Inc - $ 0 $ -5 -
Data Knights Acquisition Corp - - $ -3 -
Medical Laboratories Industry $ 236,486 $ 98,246 $ 516 417,662
  Recent News from Medical Laboratories Industry
Aclarion Inc

Aclarion Inc's Performance in Q2 2023 Raises Concerns Despite Impressive Revenue Growth



In this bearish article, we will examine Aclarion Inc's financial performance, primarily focusing on the financial time-frame closing on June 30, 2023, and its implications for the company's future. Despite an impressive revenue growth of 59.91%, there are underlying concerns that cannot be ignored. Additionally, recent trading activity and the stock's year-to-date performance indicate a declining trend. This article aims to highlight and explain these issues.
Financial Results and Revenue Growth:
Aclarion Inc showcased balanced books of $0.00 per share for the financial time-frame closing June 30, 2023. While this might initially seem positive from a profitability standpoint, it is vital to note that it remains unchanged both from the previous year and the prior reporting season. This stagnant performance raises concerns about Aclarion's ability to generate consistent profits.

Delwinds Insurance Acquisition Corp

Delwinds Insurance Acquisition Corp Reports Revenue of $0.012 Million in Q2 2023

Medical Laboratories Company Reports Modest Revenue in Q2 2023 Earnings Season
In the latest quarterly financial report released by the Medical Laboratories company, it has been revealed that the company generated revenue amounting to $0.012 million during the second quarter of the 2023 earnings season. While this figure may seem modest, it reflects the company's ongoing efforts to navigate the challenging market conditions currently impacting the healthcare industry.
Despite the relatively low revenue, Medical Laboratories remains focused on its core competencies and continues to deliver quality services to its clients. The company's strong reputation in the market has allowed it to maintain a steady stream of business, despite the headwinds it faces.

Invitae Corporation

Battling Strong Headwinds, Invitae Corporation Powers Through to Deliver Stellar Q2 2023 Earnings


Introduction
Invitae Corporation, a prominent player in the Medical Laboratories sector, reported disappointing financial results for the April to June 30 2023 time-frame. The company's earnings per share (EPS) declined to $-0.78, compared to $-10.87 a year earlier, representing a significant increase in losses. Furthermore, revenue plummeted by 11.777% to $120.53 million from $136.62 million in the prior year, while sequentially increasing by a meager 2.706% from $117.36 million.
Revenue Contrast
Contrasting with the growth observed in the remainder of the Medical Laboratories sector, which recorded a revenue increase of 3.98% in the second quarter of 2023 compared to the same reporting period a year ago, Invitae Corporation suffered a substantial decrease in revenue. This decline puts the company at a clear disadvantage within its industry, indicating a failure to adapt to current market trends and potential internal inefficiencies.

Bionexus Gene Lab Corp

Bionexus Gene Lab Corp Reports Modest Growth in Top-line Revenue during Fiscal Q2 2023



Bionexus Gene Lab Corp (BGLC) recently released its financial results for the second quarter of 2023. In order to understand the implications of these results and their potential effects on the company's future, it is crucial to delve deeper into the figures and analyze them in the context of the overall medical laboratories sector.
Revenue Growth and Comparison:
During the second quarter of 2023, BGLC's revenue witnessed a slight increase of 3.289% to reach $2.57 million. This should be seen in relation to the corresponding period a year earlier, when the company generated $2.49 million in revenue. Furthermore, Q2 2023 revenue also recorded a sequential growth of 7.978% from $2.38 million.

Biocept Inc

Biocept Inc's Second Quarter 2023 Report Reveals Shocking -94.449% Drop in Revenue: a Critical Concern for the Medical Laboratories Sector

Biocept Inc (BIOC) has recently released its second-quarter financial report for 2023, and the results are disastrous. The company's revenue plummeted by a staggering -94.449% to a mere $0.59 million. This significant decline in revenue is alarming, especially when compared to the rest of the Medical Laboratories sector, which experienced revenue growth during the same period.
Furthermore, the company's shortfall per share has widened to $-3.50, a considerable deterioration from the previous year's reporting season. In comparison to the prior reporting season, revenue deteriorated sequentially by -12.481% from $0.67 million.

Opgen Inc

OPGEN INC Faces Demand Quarter Struggles Throughout Fiscal Q2 2023

OPGEN INC: A STRUGGLING PLAYER IN THE MEDICAL LABORATORIES INDUSTRY
Opgen Inc, a leading player in the Medical Laboratories industry, has recently reported weak business performance for the quarter ending June 30, 2023. The company's losses have improved, but it still faces significant challenges that have led to a decline in revenue and an increase in the shortfall per share.
During the second quarter of 2023, Opgen Inc experienced a drop in revenue by -23.89%, with only $0.74 million generated compared to $0.97 million in the same period last year. This decline is concerning, especially considering that the overall industry witnessed a revenue gain during this time. The company's inability to capitalize on this industry growth raises questions about its competitive position and business strategy.

Psychemedics Corp

Psychemedics Corp Suffers Devastating -22.325% Revenue Drop, Reflecting Dangerous Decline in Demand for Products

Weak orders and declining revenue have led to increased losses for Psychemedics Corp in the second quarter of 2023. The company reported a net loss per share of $-0.13, up from $-0.06 in the previous year, while revenue decreased by -22.325% to $5.06 million. This represents a significant setback for the company, especially when compared to the rest of the Medical Laboratories sector, which experienced a revenue gain of 3.90% during the same period.
The decline in revenue is a concerning trend for Psychemedics Corp, as it indicates a decrease in demand for its products and services. This is further supported by the reduction in accounts receivable, which now stands at $4.0 million. Analysts believe that this decline is directly linked to the slowing demand and weak orders the company is facing.

Hh And L Acquisition Co

Hh And L Acquisition Co faces challenging operating deficit in Q2 2023, but shows promising progress compared to last year


As a shareholder of Hh And L Acquisition Co, the recent financial results for the April to June 2023 reporting cycle have left me both surprised and concerned. Having high expectations for the company's progress, it is disheartening to witness a significant operating deficit during this period.
The Medical Laboratories company's operating deficit of $-0.495455 million portrays a troubling picture. It signals a moderation in business growth, contrary to what shareholders had anticipated. However, when we examine the same period a year prior, we find a glimmer of hope. The company's operating deficit was even higher at $-0.779122 million. Thus, it can be inferred that Hh And L Acquisition Co has managed to compete more economically over time.

Data Knights Acquisition Corp

Economic Efficiency Improves as DKDCU Reduces Operating Shortfall by $0.509041 Million in Q2 2023



The Medical Laboratories sector plays a crucial role in providing essential diagnostic services to both individuals and healthcare institutions. As the reporting cycle for April to June 2023 progresses, several companies within this sector have reported their financial results. One such company is DKDCU, which recently announced an operating shortfall of $-0.285454 million for the mentioned period. This article aims to provide an explanation of DKDCU's performance, comparing it to the previous financial interval and highlighting the significance of the recent numbers.
Improvement in Economic Efficiency:
DKDCU, an evolving entity in the Medical Laboratories sector, has showcased improved economic efficiency in the April to June 2023 interval as compared to the previous year. The company reported an operating shortfall of $-0.794495 million for the corresponding period in 2022, while the current shortfall indicates a significant reduction. This improvement indicates that DKDCU has conducted its business more economically, resulting in a decrease in operating losses.

American Shared Hospital Services

American Shared Hospital Services: Surpasses Competition with Impressive Revenue Growth, Despite Minor Setback in Q2 2023



In the midst of a challenging economic climate, Medical Laboratories company has managed to showcase impressive revenue growth, outperforming its industry contemporaries. While there were signs of progress, the company fell short of breaking even in the April to June 2023 timeframe. Despite this setback, Medical Laboratories company has displayed promising potential and continues to attract attention from investors.
Strong Revenue Growth:
Medical Laboratories company reported a significant year-on-year revenue growth of 9.615%, amounting to $5.52 million in the April to June 2023 period. This growth is notably higher than the industry average, as the rest of the Medical Laboratories sector registered a 3.90% increase in revenue during the same timeframe. Such exceptional growth indicates the company's ability to capture market share and enhance its position within the industry.







Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com